David Lemus - 02 Jan 2026 Form 4 Insider Report for Silence Therapeutics plc (SLN)

Role: Director
Signature: /s/ Rhonda Hellums, Attorney-in-Fact
Issuer symbol: SLN
Transactions as of: 02 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 06 Jan 2026, 16:15:06 UTC
Previous filing: 06 Jan 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Lemus David	Director	C/O SILENCE THERAPEUTICS PLC, 12 HAMMERSMITH GROVE, LONDON, UNITED KINGDOM	/s/ Rhonda Hellums, Attorney-in-Fact	06 Jan 2026	0001717972

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SLN	Share Option (Right to Buy)	Award	$0	+90,000		$0.000000	90,000	02 Jan 2026	Ordinary Shares	90,000	$2.05	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option shall vest in equal monthly installments over a one-year period measured from one month following January 2, 2026, subject to the Reporting Person's continuous service as of each applicable vesting date.